Teresa M. Petrella
Toronto, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors - A single centre experience.
Journal: Gynecologic oncology
Published: October 05, 2025
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 12, 2024
Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review.
Journal: Surgical oncology
Published: January 17, 2024
Clinical outcomes of multisite moderate to high dose radiotherapy for patients with metastatic melanoma.
Journal: Precision radiation oncology
Published: October 11, 2023
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: October 06, 2023
Surveillance After a Previous Cutaneous Melanoma Diagnosis: A Scoping Review of Melanoma Follow-Up Guidelines.
Journal: Journal of cutaneous medicine and surgery
Published: July 25, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 22, 2023
A tailored approach to horizon scanning for cancer medicines.
Journal: Journal of cancer policy
Published: April 26, 2023
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.
Journal: Cancer medicine
Published: October 14, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 22, 2022
Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: June 06, 2022
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Journal: Cancer discovery
Published: August 21, 2021
Last Updated: 09/26/2026